BACKGROUND: Peripheral neuropathy (PN) is common among patients receiving antiretroviral therapy (ART) in resource-limited settings. We report the incidence of and risk factors for PN among human immunodeficiency virus (HIV)-infected Kenyan adults initiating ART. METHODS: An inception cohort was formed of adults initiating ART. They were screened for PN at baseline and every 3 months for 1 year. We used the validated Brief Peripheral Neuropathy Screen (BPNS) that includes symptoms and signs (vibration perception and ankle reflexes) of PN. RESULTS: Twenty-two (11%) of 199 patients had PN at baseline screening. One hundred fifty patients without evidence of PN at baseline were followed for a median of 366 days (interquartile range, 351-399). The incidence of PN was 11.9 per 100 person-years (95% confidence interval [CI], 6.9-19.1) and was higher in women than men (17.7 vs 1.9 per 100 person-years; rate ratio, 9.6; 95% CI, 1.27-72, P = .03). In stratified analyses, female sex remained statistically significant after adjustment for each of the following variables: age, CD4 cell count, body mass index, ART regimen, and tuberculosis treatment. Stratifying hemoglobin levels decreased the hazard ratio from 9.6 to 7.40 (P = .05), with higher levels corresponding to a lower risk of PN. CONCLUSIONS: HIV-infected Kenyan women were almost 10 times more likely than men to develop PN in the first year of ART. The risk decreased slightly at higher hemoglobin levels. Preventing or treating anemia in women before ART initiation and implementing BPNS during the first year of ART, the period of highest risk, could ameliorate the risk of PN.
BACKGROUND:Peripheral neuropathy (PN) is common among patients receiving antiretroviral therapy (ART) in resource-limited settings. We report the incidence of and risk factors for PN among human immunodeficiency virus (HIV)-infected Kenyan adults initiating ART. METHODS: An inception cohort was formed of adults initiating ART. They were screened for PN at baseline and every 3 months for 1 year. We used the validated Brief Peripheral Neuropathy Screen (BPNS) that includes symptoms and signs (vibration perception and ankle reflexes) of PN. RESULTS: Twenty-two (11%) of 199 patients had PN at baseline screening. One hundred fifty patients without evidence of PN at baseline were followed for a median of 366 days (interquartile range, 351-399). The incidence of PN was 11.9 per 100 person-years (95% confidence interval [CI], 6.9-19.1) and was higher in women than men (17.7 vs 1.9 per 100 person-years; rate ratio, 9.6; 95% CI, 1.27-72, P = .03). In stratified analyses, female sex remained statistically significant after adjustment for each of the following variables: age, CD4 cell count, body mass index, ART regimen, and tuberculosis treatment. Stratifying hemoglobin levels decreased the hazard ratio from 9.6 to 7.40 (P = .05), with higher levels corresponding to a lower risk of PN. CONCLUSIONS:HIV-infected Kenyanwomen were almost 10 times more likely than men to develop PN in the first year of ART. The risk decreased slightly at higher hemoglobin levels. Preventing or treating anemia in women before ART initiation and implementing BPNS during the first year of ART, the period of highest risk, could ameliorate the risk of PN.
Authors: Peter Guarino; Donna L Lamping; Diana Elbourne; James Carpenter; Peter Peduzzi Journal: J Clin Epidemiol Date: 2006-03-24 Impact factor: 6.437
Authors: Kenneth A Lichtenstein; Carl Armon; Anna Baron; Anne C Moorman; Kathleen C Wood; Scott D Holmberg Journal: Clin Infect Dis Date: 2004-12-06 Impact factor: 9.079
Authors: Fatu Forna; Cheryl A Liechty; Peter Solberg; Fred Asiimwe; Willy Were; Jonathan Mermin; Prosper Behumbiize; Tony Tong; John T Brooks; Paul J Weidle Journal: J Acquir Immune Defic Syndr Date: 2007-04-01 Impact factor: 3.731
Authors: C William Wester; Soyeon Kim; Hermann Bussmann; Ava Avalos; Ndwapi Ndwapi; Trevor F Peter; Tendani Gaolathe; Andrew Mujugira; Lesego Busang; Chris Vanderwarker; Peter Cardiello; Onalethata Johnson; Ibou Thior; Patson Mazonde; Howard Moffat; Max Essex; Richard Marlink Journal: J Acquir Immune Defic Syndr Date: 2005-11-01 Impact factor: 3.731
Authors: D M Simpson; D Kitch; S R Evans; J C McArthur; D M Asmuth; B Cohen; K Goodkin; M Gerschenson; Y So; C M Marra; R Diaz-Arrastia; S Shriver; L Millar; D B Clifford Journal: Neurology Date: 2006-06-13 Impact factor: 9.910
Authors: Peter Peduzzi; Zhenchao Guo; Richard A Marottoli; Thomas M Gill; Katy Araujo; Heather G Allore Journal: J Clin Epidemiol Date: 2006-09-28 Impact factor: 6.437
Authors: Alejandro Arenas-Pinto; Jennifer Thompson; Godfrey Musoro; Hellen Musana; Abbas Lugemwa; Andrew Kambugu; Aggrey Mweemba; Dickens Atwongyeire; Margaret J Thomason; A Sarah Walker; Nicholas I Paton Journal: J Neurovirol Date: 2015-08-25 Impact factor: 2.643
Authors: Hayley Goullee; Antonia L Wadley; Catherine L Cherry; Richard J N Allcock; Michael Black; Peter R Kamerman; Patricia Price Journal: J Neurovirol Date: 2016-01-19 Impact factor: 2.643
Authors: Andy Tran; Kiran T Thakur; Noeline Nakasujja; Gertrude Nakigozi; Alice Kisakye; James Batte; Richard Mayanja; Aggrey Anok; Ronald H Gray; Maria J Wawer; Leah H Rubin; Ned Sacktor; Deanna Saylor Journal: J Neurol Sci Date: 2020-12-24 Impact factor: 3.181
Authors: Frank Ndaks Ndakala; Julius Otieno Oyugi; Margaret Ng'wono Oluka; Joshua Kimani; Alexandra Jablonka; Georg Martin Norbert Behrens Journal: Pan Afr Med J Date: 2016-09-20
Authors: Deanna Saylor; Gertrude Nakigozi; Noeline Nakasujja; Kevin Robertson; Ronald H Gray; Maria J Wawer; Ned Sacktor Journal: Neurology Date: 2017-07-05 Impact factor: 9.910